4576 D.Western Therapeutics Institute, Inc. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4576

TSE Growth

D.Western Therapeutics Institute, Inc.

199

JPY

-26

(-11.56%)

Dec 23, 3:16 pm JST

1.23

USD

Dec 23, 1:00 am EST

Result

PTS

outside of trading hours

198.9

Dec 23, 3:14 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2020	355	-265	-289	-276	-10.2	0	Feb 12, 2021	J-GAAP
Dec, 2021	414	-171	-159	-148	-5.1	0	Feb 10, 2022	J-GAAP
Dec, 2022	448	-305	-295	-429	-14.5	0	Feb 13, 2023	J-GAAP
Dec, 2023	428	-798	-796	-812	-25.6	0	Feb 9, 2024	J-GAAP
Dec, 2024 Guidance	400	-1,500	-1,510	-1,510	-36.9	0	Feb 9, 2024	J-GAAP
YoY	-6.5%	-88.0%	-89.7%	-86.0%	-44.4%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2019	Feb 14, 2019	500	30	20	60	0	J-GAAP
	Dec 12, 2019	580	110	100	130	0	J-GAAP
Results	Feb 13, 2020	580	117	109	133	0	J-GAAP
Dec, 2020	Feb 13, 2020	Available in future release
	Apr 16, 2020
	Jan 14, 2021
Results	Feb 12, 2021
Dec, 2021	Feb 12, 2021
	Oct 11, 2021
	Nov 19, 2021
Results	Feb 10, 2022
Dec, 2022	Feb 10, 2022
	Nov 18, 2022
Results	Feb 13, 2023
Dec, 2023	Feb 13, 2023
	Dec 14, 2023
Results	Feb 9, 2024
Dec, 2024	Feb 9, 2024	400	-1,500	-1,510	-1,510	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 2004	95	－	Available in future release
Dec, 2005	40	-57.9
Dec, 2006	135	+237.5
Dec, 2007	30	-77.8
Dec, 2008	37	+23.3
Dec, 2009	0	-100.0
Dec, 2010	ー	－
Dec, 2011	20	－
Dec, 2012	112	+460.0
Dec, 2013	80	-28.6
Dec, 2014	80	0.0
Dec, 2015	61	-23.8
Dec, 2016	168	+175.4
Dec, 2017	254	+51.2
Dec, 2018	292	+15.0
Dec, 2019	580	+98.6
Dec, 2020	355	-38.8
Dec, 2021	414	+16.6
Dec, 2022	448	+8.2
Dec, 2023	428	-4.5
Dec, 2024 Guidance	400	-6.5	-1,500	-88.0	-1,510	-89.7	-36.9	-44.1

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2022	448	-305	-68	-22.23	-15.84	0.17	-14.5
Dec, 2023	428	-798	-186	-51.80	-30.47	0.16	-25.6
Dec, 2024 Guidance	400	-1,500	-375	-148.62	-68.92	0.18	-36.9

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	580	117	109	133	159,744
Fiscal Year	Dec, 2019	Dec, 2019	Dec, 2019	Dec, 2019	Dec, 2004

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2021	213	-80	-77	-66	-2.3	0	Feb 10, 2022	J-GAAP
Jul - Dec, 2022	238	-173	-177	-319	-10.8	0	Feb 13, 2023	J-GAAP
Jul - Dec, 2023	241	-540	-542	-565	-17.8	0	Feb 9, 2024	J-GAAP
Jul - Dec, 2024 Guidance	177	-1,051	-1,051	-990	-24.2	0	Aug 9, 2024	J-GAAP
YoY	-26.6%	-94.6%	-93.9%	-75.2%	-36.1%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2021	-171	-287	-176	-111	-104	1,933	78.51	J-GAAP
Dec, 2022	-305	-493	-354	-139	867	2,334	78.96	J-GAAP
Dec, 2023	-798	-601	-586	-15	134	1,867	78.68	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2022	309	-251	-239	-226	-7.7	ー	Nov 10, 2022	J-GAAP
Jan - Sep, 2023	313	-457	-453	-443	-14.0	ー	Nov 10, 2023	J-GAAP
Jan - Sep, 2024	348	-647	-665	-727	-21.6	ー	Nov 14, 2024	J-GAAP
YoY	+11.2%	-41.6%	-46.8%	-64.1%	-54.1%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	139	-54	-56	-203	-6.9	-38.8	Feb 13, 2023	J-GAAP
Jan - Mar, 2023	90	-101	-101	-97	-3.1	-112.2	May 12, 2023	J-GAAP
Apr - Jun, 2023	97	-157	-153	-150	-4.8	-161.9	Aug 10, 2023	J-GAAP
Jul - Sep, 2023	126	-199	-199	-196	-6.2	-157.9	Nov 10, 2023	J-GAAP
Oct - Dec, 2023	115	-341	-343	-369	-11.6	-296.5	Feb 9, 2024	J-GAAP
Jan - Mar, 2024	104	-318	-320	-320	-10.0	-305.8	May 13, 2024	J-GAAP
Apr - Jun, 2024	119	-131	-139	-200	-6.2	-110.1	Aug 9, 2024	J-GAAP
Jul - Sep, 2024	125	-198	-206	-207	-6.2	-158.4	Nov 14, 2024	J-GAAP
YoY	-0.8%	+0.5%	-3.5%	-5.6%	+0.8%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	129	+48.3	Available in future release
Jan - Mar, 2020	74	-73.1
Apr - Jun, 2020	77	-12.5
Jul - Sep, 2020	89	+1.1
Oct - Dec, 2020	115	-10.9
Jan - Mar, 2021	89	+20.3
Apr - Jun, 2021	112	+45.5
Jul - Sep, 2021	114	+28.1
Oct - Dec, 2021	99	-13.9
Jan - Mar, 2022	109	+22.5
Apr - Jun, 2022	101	-9.8
Jul - Sep, 2022	99	-13.2
Oct - Dec, 2022	139	+40.4
Jan - Mar, 2023	90	-17.4
Apr - Jun, 2023	97	-4.0
Jul - Sep, 2023	126	+27.3
Oct - Dec, 2023	115	-17.3
Jan - Mar, 2024	104	+15.6
Apr - Jun, 2024	119	+22.7
Jul - Sep, 2024	125	-0.8	-198	+0.5	-206	-3.5	-6.2	0.0

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	275	145	143	152	5.8
Fiscal Year	Mar, 2019	Mar, 2019	Mar, 2019	Mar, 2019	Mar, 2019

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2021	68.27	81.4	2,462	2,004	-1,200	0.17	Feb 10, 2022	J-GAAP
Dec, 2022	60.14	62.8	2,956	1,856	-1,629	0.52	Feb 13, 2023	J-GAAP
Dec, 2023	39.81	53.9	2,373	1,279	-2,442	0.69	Feb 9, 2024	J-GAAP
Jan - Sep, 2024	ー	46.4	2,191	1,016	-3,169	1.04	Nov 14, 2024	J-GAAP

D.Western Therapeutics Institute, Inc.(4576) Financial Results